Carregant...
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
The KRAS gene is frequently mutated in multiple cancer types, but it fell off the drug discovery radar for many years because of its inherent “undruggable” structure and undefined biological properties. As reported in the paper entitled “Suppression of KRas-mutant cancer through the combined inhibit...
Guardat en:
| Publicat a: | Chin J Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5086049/ https://ncbi.nlm.nih.gov/pubmed/27793187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0154-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|